Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $264.6 million versus the consensus estimate of $262.44 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.